Fentanyl sublingual spray

DRUG5 trials

Sponsors

INSYS Therapeutics Inc, M.D. Anderson Cancer Center

Conditions

Advanced CancersCancerMucositisPainPharmacologyUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Fentanyl Sublingual Spray in Opioid Naive Participants

CompletedNCT02641340

INSYS Therapeutics IncPharmacology

Start: 2016-01-31End: 2016-03-31Updated: 2016-03-30

Phase 2

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

CompletedNCT02597478

M.D. Anderson Cancer CenterAdvanced Cancers

Start: 2016-01-04End: 2021-01-27Updated: 2021-02-09

Phase 3

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

CompletedNCT00538863

INSYS Therapeutics IncCancer, Pain

Start: 2007-12-31End: 2010-10-31Updated: 2013-10-11

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

CompletedNCT00538850

INSYS Therapeutics IncCancer

Start: 2007-10-31End: 2010-10-31Updated: 2014-03-05

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

CompletedNCT00956254

INSYS Therapeutics IncMucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific

Start: 2009-10-31End: 2010-10-31Updated: 2013-09-05

Related Papers

Pharmacokinetics of Fentanyl Sublingual Spray in Opioid-Naïve Participants: Results of a Phase 1, Multiple Ascending Dose Study.

2018-08-013 citations

Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a multiple ascending dose study in opioid-naïve healthy volunteers

Current Medical Research and Opinion2017-09-235 citations

Fentanyl Sublingual Spray for Breakthrough Cancer Pain in Patients Receiving Transdermal Fentanyl

Pain Management2016-03-297 citations

Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.

Journal of Clinical Oncology2014-11-011 citations

Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.

2012-05-0237 citations